Transplantation · 2026
Molecular Classification Predicts Clinical Outcomes of Kidney Transplant Recipients With Microvascular Inflammation, Donor-specific Antibodies-negative and C4d-negative.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Aziz Fahad, Zhang Hao, Chuang Peale, Tian Wenlan, Zeng Jijiao, Lu James, Shen Ling, Gulbahce Natali, Kobrle Jana, Tobin Lisa, Woodward Robert, Coley Shana, Napier Johnathan, Djamali Arjang, Garg Neetika
Аннотация
BACKGROUND: Microvascular inflammation (MVI), donor-specific antibodies (DSAs)-negative and C4d-negative, was recently defined as a distinct phenotype by Banff 2022 and has been associated with adverse clinical outcomes. We have developed a model for rejection-related molecular classification of renal allograft biopsies using gene expression profiling of formalin-fixed paraffin-embedded renal biopsy tissue and evaluated its performance in patients with MVI.
METHODS: Using this updated gene expression profiling-based multiclass model, we evaluated 138 biopsy specimens obtained from a large US transplant center, which included 42 biopsies diagnosed as MVI, DSA-negative, and C4d-negative. Clinical outcomes of patients in this MVI biopsy group were analyzed in relation to their molecular classifications.
RESULTS: The molecular rejection classifications exhibited robust concordance with histology diagnoses of no rejection, antibody-mediated rejection, and T-cell-mediated rejection in this independent cohort, with concordance rates varying in each group from 85% to 93%. The molecular classification also showed a significant association with differential renal function and graft survival in the MVI, DSA-negative, and C4d-negative group.
CONCLUSIONS: Our model demonstrates significant molecular differentiation among antibody-mediated rejection, T-cell-mediated rejection, and no rejection. In addition, our model classified MVI, DSA-negative, and C4d-negative samples into molecular subgroups associated with divergent clinical outcomes.
METHODS: Using this updated gene expression profiling-based multiclass model, we evaluated 138 biopsy specimens obtained from a large US transplant center, which included 42 biopsies diagnosed as MVI, DSA-negative, and C4d-negative. Clinical outcomes of patients in this MVI biopsy group were analyzed in relation to their molecular classifications.
RESULTS: The molecular rejection classifications exhibited robust concordance with histology diagnoses of no rejection, antibody-mediated rejection, and T-cell-mediated rejection in this independent cohort, with concordance rates varying in each group from 85% to 93%. The molecular classification also showed a significant association with differential renal function and graft survival in the MVI, DSA-negative, and C4d-negative group.
CONCLUSIONS: Our model demonstrates significant molecular differentiation among antibody-mediated rejection, T-cell-mediated rejection, and no rejection. In addition, our model classified MVI, DSA-negative, and C4d-negative samples into molecular subgroups associated with divergent clinical outcomes.